República de Colombia
Ministerio de Salud y Protección Social
Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA

RESOLUCIÓN No. 2016014463 DE 25 de Abril de 2016
Por la cual se concede un Registro Sanitario

El Director de Dispositivos Médicos y Otras Tecnologías del Instituto Nacional de Vigilancia de Medicamentos y Alimentos INVIMA, en ejercicio de las facultades Legales conferidas en el Decreto 2078 de 2012, Decreto Reglamentario 4725 de 2005, y ley 1437 de 2011.

ANTECEDENTES

Que mediante Radicado No. 2015151799 de fecha 13 de Noviembre de 2015, el Doctor Carlos Fernando Moreno García, actuando en calidad de Apoderado de la Sociedad LG LIFE SCIENCES, LTD con domicilio en JEOLLABUK-DO - REPUBLICA DE COREA (COREA DEL SUR), solicitó Registro Sanitario para el producto HYRUAN ONE - VISCO SUPLEMENTO ABSORBIBLE PARA OSTEOARTRITIS, en la modalidad de Importar y Vender

Que mediante Auto No. 2016000617 de fecha 22 de Enero de 2016, se solicitó al interesado:

"1. Allegar corregido el formulario, en el sentido de mencionar en el nombre genérico del producto, la descripción del mismo, toda vez que el nombre "HYRUAN ONE", no permite saber a que corresponde el producto (Ej: Nombre del producto: HYRUAN ONE, Nombre genérico: Visco suplemento absorbible para osteoartritis.), junto con el sticker del importador, en el sentido de mencionar el nombre que se dejará como genérico.
2. Allegar el historial comercial emitido por el fabricante, manifestando, si se han presentado Alertas Sanitarias involucradas con el producto, acorde al literal a del artículo 29 del Decreto 4725 de 2005. Lo anterior se solicita, por cuanto en el historial comercial allegado se indica el reporte de casos, razón por la cual, deberá aportar historial comercial del fabricante en el que indique si el producto ha presentado o no ALERTAS SANITARIAS involucradas con el producto. Cabe señalar que una alerta sanitaria es un proceso en el que se manifiesta toda sospecha de una situación de riesgo potencial asociada a la utilización de un Dispositivos Médico o Equipo Biomédico, que pueda afectar la salud de la población o pueda tener trascendencia social, la cual puede llegarse a presentar por un caso o un número de casos reportados con una misma asociación o relación causal entre un evento, teniendo en cuenta que debe tener traducción al español.
3. Allegar corregido el formulario en el sentido de mencionar el domicilio y la razón social del fabricante que se encuentra en las etiquetas, toda vez que no coincide, de conformidad con el artículo 54, 55 del Decreto 4725 de 2005."

Que mediante escrito No. 2016017899 de fecha 15 de Febrero de 2015, el Doctor Carlos Fernando Moreno García, actuando en calidad de Apoderado, allegó respuesta al Auto No. 2016000617.

CONSIDERACIONES DEL DESPACHO

Que el estudio de respuesta a Auto se considera satisfactorio toda vez que el interesado allega el formulario corregido con el nombre genérico y la razón social y domicilio del fabricante, y allega historial comercial emitido por el fabricante donde se presentan las alertas sanitarias del producto, ante este Instituto con la documentación allegada, previo estudio técnico y legal de la Dirección de Dispositivos Médicos y Otras Tecnologías del INVIMA, se emitió concepto favorable para la autorización de este Registro Sanitario.

En consecuencia este Instituto,

RESUELVE

ARTICULO PRIMERO.- Conceder REGISTRO SANITARIO por el término de DIEZ (10) años a

PRODUCTO:	HYRUAN ONE - VISCO SUPLEMENTO ABSORBIBLE PARA OSTEOARTRITIS
MARCA:	HYRUAN ONE
REGISTRO SANITARIO No.:	INVIMA 2016DM-0014594
TIPO DE REGISTRO:	IMPORTAR Y VENDER
TITULAR(ES):	LG LIFE SCIENCES, LTD con domicilio en COREA DEL SUR
FABRICANTE(S):	LG LIFE SCIENCES, LTD con domicilio en COREA DEL SUR
IMPORTADOR(ES):	CALIER FARMACEUTICA DE COLOMBIA S.A con domicilio en BOGOTA - D.C.
ACONDICIONADOR(ES):	DHL GLOBAL FORWARDING ZONA FRANCA (COLOMBIA) S.A. con domicilio en BOGOTA - D.C.

República de Colombia
Ministerio de Salud y Protección Social
Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA

RESOLUCIÓN No. 2016014463 DE 25 de Abril de 2016
Por la cual se concede un Registro Sanitario

El Director de Dispositivos Médicos y Otras Tecnologías del Instituto Nacional de Vigilancia de Medicamentos y Alimentos INVIMA, en ejercicio de las facultades Legales conferidas en el Decreto 2078 de 2012, Decreto Reglamentario 4725 de 2005, y ley 1437 de 2011.

TIPQ DE DISPOSITIVO	INVASIVO
RIESGO:	III
COMPOSICIÓN:	BDDE- GEL DE HIALURONATO DE SODIO DE ENLACE ENTRECRUZADO 3,0G EQUIVALENTE A 60 MG DE BDDE- HIALURONATO DE SODIO DE ENLACE ENTRECRUZADO.
USOS:	PARA USAR COMO TRATAMIENTO SINTOMÁTICO PARA OSTEOARTRITIS DE LAS ARTICULACIONES QUE SOPORTAN PESO, INCLUYENDO RODILLA, HOMBRO, TOBILLO Y CADERA.
PRESENTACIONES COMERCIALES:	1 JERINGA PRE- LLENADA (3,0 ML)
EXPEDIENTE No.:	20101898
RADICACIÓN No.:	2015151799

ARTICULO SEGUNDO.- Se aprueban las etiquetas según radicado No. 2015151799

ARTICULO TERCERO.- Contra la presente resolución procede únicamente el Recurso de Reposición, que deberá interponerse ante la Dirección de Dispositivos Médicos y Otras Tecnologías del INVIMA, dentro de los DIEZ (10) días siguientes a su notificación, en los términos señalados en el Código de Procedimiento Administrativo y de lo Contencioso Administrativo.

ARTICULO CUARTO.- La presente resolución rige a partir de la fecha de su expedición.

COMUNIQUESE, NOTIFIQUESE Y CUMPLASE
Dada en Bogotá D.C. a los 25 de Abril de 2016



ELKIN HERNAN OTALVARO CIFUENTES
DIRECTOR DE DISPOSITIVOS MÉDICOS Y OTRAS TECNOLOGÍAS
Proyectó: Legal: hdemoyag, Técnico: jloram Revisó: cordina_varios

Firma válida

Digitally signed by ELKIN HERNAN OTALVARO CIFUENTES
Date: 2016.04.26 10:35:
Reason: firma
Location: Bogota, CO

Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA
Carrera 10 N.° 64/28
PBX: 2948700

Bogotá - Colombia
www.invima.gov.co

INSTITUTO NACIONAL DE VIGILANCIA DE MEDICAMENTOS Y ALIMENTOS

INVIMA

A la fecha notifíquese personalmente a Omaira Chego

Con identificación No. 52270594 de Bta

y T.P. No. _____ de _____

de la Resolución No. 2016014463 de fecha 25-04-16

En Bogotá 29 ABR 2016 Hora _____

Notificado Omaira Chego

Notificador _____

60*40mm


IPM206469-2
Another synovia
Hyruan ONE
Cross-linked hyaluronic acid
3.0mL X 1syringe
Absorbable viscosupplement for osteoarthritis
LOT
STERILE
LG Life Sciences

사이즈 변경하면서 칼선 임의변경



LG Life Sciences

129, Seokam-ro, Iksan-si,
Jeollabuk-do, Korea

【Intended use】 For use as a symptomatic treatment for osteoarthritis of weight bearing joints including knee, shoulder, hip and ankle.

【Composition】

Active ingredient: BDDE-crosslinked sodium hyaluronate gel - 3.0g
(BDDE-crosslinked sodium hyaluronate - 60mg)

【Contents】 3.0mL/syringe X 1syringe

【Storage】 Store at 1~30˚C free from light, in a hermetic container.

[Uso previsto] Para uso en el tratamiento sintomático de osteoartritis de articulaciones que soportan peso, incluyendo rodilla, hombro, cadera y tobillo.

[Composición]
Ingrediente Activo: BDDE - 3.0 g de gel de hialuronato de sodio entrecruzado
(BDDE - hialuronato de sodio entrecruzado – 60 mg)

[Contenido] 3.0mL /jeringa x 1 jeringa

[Almacenamiento] Almacenar entre 1-30 °C alejado de la luz, en un contenedor hermético.

125*190mm(front)

125*190mm(back)

Absorbable viscosupplement for osteoarthritis

IPM206472-2

Another synovia
Hyruan ONE
Cross-linked hyaluronic acid

Description

Hyruan ONE is a milestone viscosupplementation treatment used to relieve pain associated with osteoarthritis of the knee, shoulder, hip and ankle. Hyruan ONE is a clear, colorless and viscous gel containing 60mg BDDE(1,4-butanediol diglycidyl ether)-crosslinked sodium hyaluronate in a 3mL pre-filled syringe with rubber stoppers on the both ends.

Contents

Each Hyruan ONE (volume of 3.0mL/syringe) contains:
Active ingredient: BDDE-crosslinked sodium hyaluronate gel - 3.0g
(BDDE-crosslinked sodium hyaluronate - 60mg)

Intended Use

For use as a symptomatic treatment for osteoarthritis of weight bearing joints including knee, shoulder, hip and ankle.

Dosage

Hyruan ONE is a single dose for single injection, and should only be injected once per treatment course. The recommended dose is 3mL for knee, shoulder or hip joint and 1-2mL for ankle joint.

Mode of Action

Naturally-occurring hyaluronic acid in the various part of the body acts in the joints as a shock absorber, protects cartilage, and relieves pain associated with osteoarthritis.

Contraindications

1) Hyruan ONE should not be injected:
- To patients who are known to be sensitive to the product or its ingredient(s)
- To patients with an infection or severe inflammation at joint cavity
- To patients with a disease or infection of skin near the injection site

2) Hyruan ONE should be injected with cautions:
- In patients with hypersensitivity to other substance
- In patients with liver disease or prior history of the liver disease

Adverse Events

1) Serious adverse events
Shock: since symptoms of shock (frequency unknown) may occur, careful observation should be made. In case abnormalities are noticed, administration should be discontinued and proper measures should be taken.

2) Reported adverse events in clinical trials
In a pivotal clinical trial of Hyruan ONE in patients with the knee osteoarthritis (a total of 285 subjects), the occurrence rate of local reaction at injection site after injection into articular cavity was 48.9% (68 /139 subjects) in the study group and 49.3% (72/146 subjects) in the control group. The reported adverse events are shown in Table 1. The serious adverse events were reported in the decreasing order of pain (7.2% of the study group, 6.2% of the control group, redness (5.0% of the study group, 2.1% of the control group) and so on. Adverse events lasting over a week were pain 5.3%, redness 1.4%, swelling and warmth each accounting for 1.0%, yet all of them completely resolved in two weeks without any special treatment.

Table 1. Reported local reaction at injection area in the clinical trial

Adverse events	Hyruan ONE N=139(%)	Hyruan Plus*(Control) N=146(%)
Pain	60(43.2)	55(37.7)
Redness	27(19.4)	31(21.2)
Swelling	17(12.2)	21(14.4)
Warmth	33(23.7)	30(20.5)

* Hyruan Plus, requiring three weekly injections, is a viscosupplement for osteoarthritis developed by LG Life Sciences, Ltd.

3) Of the patients with the knee osteoarthritis (285 subjects), the occurrence rate of the adverse events excluding ones occurred at the injection site is 34.5% (48/139, 73 cases) for the study group and 28.8% (42/146, 63 cases) for the control group. Most of them were mild to moderate. Table 2 indicates the adverse events occurred in more than 1% of the study group.

Table 2. Adverse events reported in more than 1% of the subjects treated with Hyruan ONE in the clinical trial

Adverse events	Hyruan ONE N=139(%)	Hyruan Plus*(Control) N=146(%)
Nasopharyngitis	7 (5)	3 (2.1)
Pain	4 (2.9)	1 (0.7)
Warmth	3 (2.2)	0 (0)
Upper respiratory tract infection	3 (2.2)	0 (0)
Pain in extremity	3 (2.2)	6 (4.1)
Cystitis	2 (1.4)	2 (1.4)
Dyspepsia	2 (1.4)	1 (0.7)
Parathesia	2 (1.4)	0 (0)
Redness	2 (1.4)	0 (0)
Joint swelling	2 (1.4)	0 (0)
Muscloskeletal pain	2 (1.4)	0 (0)
Plantar fasciitis	2 (1.4)	0 (0)

Precautions

1) General precaution:
- Administration of Hyruan ONE to severely inflamed joints caused by deformative osteoarthritis can lead to exacerbation of the local inflammation symptom. Thus, Hyruan ONE is desired to be given after the removal of existing inflammation symptoms.
- Administration of Hyruan ONE may occasionally cause local pain or swelling. Thus, patients should be informed to avoid strenuous exercise or action leading joint pain of knee up to 48 hours after administration, and actions such as local relaxation should be guided after injection.
- Leakage of Hyruan ONE other than articular cavity might cause pain. Thus, Hyruan ONE should be accurately injected into articular cavity.

2) Precautions in use:
- The product should be administered by trained doctors.
- Since Hyruan ONE is injected directly into the joints, administration should be performed under intact sterilization status.
- In case of retention of articular fluid, the fluid should be removed by puncturing prior to administration of Hyruan ONE.
- Intravascular injection, extra-articular injection or injection in the synovial tissues should be avoided.
- It is desirable to administer the product using enclosed needles.
- Care should be taken with a disinfectant fourth-grade ammonium salt such as benzalkonium chloride and chlorohexidine.
- Hyruan ONE is intended for single use only. No re-sterilization or reuse is allowed.
- The injection site must be sterilized either by alcohol or other disinfecting solution prior to administration.
- Used syringe, needle and unused materials all need to be discarded after administration.
- In case Hyruan ONE is administered into both sides of knee, a separate product should be applied for each administration.

3) Precautions in handling
- Hyruan ONE should be kept away from children.
- Hyruan ONE should be kept in original packaging; storing Hyruan ONE in a different packaging can cause misuse of product or decline the product quality.

Incompatibilities

Incompatibilities of Hyruan ONE with other drug substances have not been established.

Use in specific populations

1) Pregnancy
Safety and efficacy of Hyruan ONE in pregnant women have not been established so that Hyruan ONE should be cautiously administered to pregnant women or woman having possibility to be pregnant only when the benefits of treatments outweigh danger.

2) Nursing mothers
Safety and efficacy of Hyruan ONE in nursing mother have not been established, thus Hyruan ONE should be cautiously administered to nursing mother only when the benefits of treatments outweigh danger.

3) Pediatrics
The pediatric Safety and efficacy of Hyruan ONE have not been established thus Hyruan ONE should be administered to children with caution when administered unavoidably.

4) Geriatrics
Since physiological function of geriatrics has a declining tendency, administration should be made carefully. Difference in the incidence of reaction rate after administration of Hyruan ONE between geriatrics and non-geriatric group was not observed in the clinical trial.

Storage condition

Store at 1~30℃ free from light, in a hermetic container.

How supplied

3.0mL/syringe × 1syringe

Shelf life

24 months

※Date of Issue : February 11, 2015

Symbols on packaging

	Do not resterilize	1℃ 30℃	Temperature limitation
	Do not re-use		Keep away from sunlight
	Consult instructions for use	STERILE	Sterilized stream or dry heat
	Do not use if package is damaged		Keep away from rain
	Caution		Date of manufacture
	Manufacturer		Use-by date
LOT	Batch code		

LG Life Sciences
129, Seokam-ro, Iksan-si,
Jeollabuk-do, Korea

125*190mm(front)

Absorbable viscosupplement for osteoarthritis

IPM206472-2

Another synovia

Hyruan ONE

Cross-linked hyaluronic acid

Description

Hyruan ONE is a milestone viscosupplementation treatment used to relieve pain associated with osteoarthritis of the knee, shoulder, hip and ankle. Hyruan ONE is a clear, colorless and viscous gel containing 60mg BDDE(1,4-butanediol diglycidyl ether)-crosslinked sodium hyaluronate in a 3mL pre-filled syringe with rubber stoppers on the both ends.

Contents

Each Hyruan ONE (volume of 3.0mL/syringe) contains:
Active ingredient: BDDE-crosslinked sodium hyaluronate gel - 3.0g
(BDDE-crosslinked sodium hyaluronate - 60mg)

Intended Use

For use as a symptomatic treatment for osteoarthritis of weight bearing joints including knee, shoulder, hip and ankle.

Dosage

Hyruan ONE is a single dose for single injection, and should only be injected once per treatment course. The recommended dose is 3mL for knee, shoulder or hip joint and 1-2mL for ankle joint.

Mode of Action

Naturally-occurring hyaluronic acid in the various part of the body acts in the joints as a shock absorber, protects cartilage, and relieves pain associated with osteoarthritis.

Contraindications

1) Hyruan ONE should not be injected:
- To patients who are known to be sensitive to the product or its ingredient(s)
- To patients with an infection or severe inflammation at joint cavity
- To patients with a disease or infection of skin near the injection site

2) Hyruan ONE should be injected with cautions:
- In patients with hypersensitivity to other substance
- In patients with liver disease or prior history of the liver disease

Adverse Events

1) Serious adverse events
Shock: since symptoms of shock (frequency unknown) may occur, careful observation should be made. In case abnormalities are noticed, administration should be discontinued and proper measures should be taken.

2) Reported adverse events in clinical trials
In a pivotal clinical trial of Hyruan ONE in patients with the knee osteoarthritis (a total of 285 subjects), the occurrence rate of local reaction at injection site after injection into articular cavity was 48.9% (68 /139 subjects) in the study group and 49.3% (72/146 subjects) in the control group. The reported adverse events are shown in Table 1. The serious adverse events were reported in the decreasing order of pain (7.2% of the study group, 6.2% of the control group, redness (5.0% of the study group, 2.1% of the control group) and so on. Adverse events lasting over a week were pain 5.3%, redness 1.4%, swelling and warmth each accounting for 1.0%, yet all of them completely resolved in two weeks without any special treatment.

Table 1. Reported local reaction at injection area in the clinical trial

Adverse events	Hyruan ONE N=139(%)	Hyruan Plus*(Control) N=146(%)
Pain	60(43.2)	55(37.7)
Redness	27(19.4)	31(21.2)
Swelling	17(12.2)	21(14.4)
Warmth	33(23.7)	30(20.5)

* Hyruan Plus, requiring three weekly injections, is a viscosupplement for osteoarthritis developed by LG Life Sciences, Ltd.

3) Of the patients with the knee osteoarthritis (285 subjects), the occurrence rate of the adverse events excluding ones occurred at the injection site is 34.5% (48/139, 73 cases) for the study group and 28.8% (42/146, 63 cases) for the control group. Most of them were mild to moderate. Table 2 indicates the adverse events occurred in more than 1% of the study group.

Table 2. Adverse events reported in more than 1% of the subjects treated with Hyruan ONE in the clinical trial

Adverse events	Hyruan ONE N=139(%)	Hyruan Plus*(Control) N=146(%)
Nasopharyngitis	7 (5)	3 (2.1)
Pain	4 (2.9)	1 (0.7)
Warmth	3 (2.2)	0 (0)
Upper respiratory tract infection	3 (2.2)	0 (0)
Pain in extremity	3 (2.2)	6 (4.1)
Cystitis	2 (1.4)	2 (1.4)
Dyspepsia	2 (1.4)	1 (0.7)
Paresthesia	2 (1.4)	0 (0)
Redness	2 (1.4)	0 (0)
Joint swelling	2 (1.4)	0 (0)
Musculoskeletal pain	2 (1.4)	0 (0)
Plantar fasciitis	2 (1.4)	0 (0)

125*190mm(back)

Precautions

1) General precaution:
- Administration of Hyruan ONE to severely inflamed joints caused by deformative osteoarthritis can lead to exacerbation of the local inflammation symptom. Thus, Hyruan ONE is desired to be given after the removal of existing inflammation symptoms.
- Administration of Hyruan ONE may occasionally cause local pain or swelling. Thus, patients should be informed to avoid strenuous exercise or action leading joint pain of knee up to 48 hours after administration, and actions such as local relaxation should be guided after injection.
- Leakage of Hyruan ONE other than articular cavity might cause pain. Thus, Hyruan ONE should be accurately injected into articular cavity.

2) Precautions in use:
- The product should be administered by trained doctors.
- Since Hyruan ONE is injected directly into the joints, administration should be performed under intact sterilization status.
- In case of retention of articular fluid, the fluid should be removed by puncturing prior to administration of Hyruan ONE.
- Intravascular injection, extra-articular injection or injection in the synovial tissues should be avoided.
- It is desirable to administer the product using enclosed needles.
- Care should be taken with a disinfectant fourth-grade ammonium salt such as benzalkonium chloride and chlorohexidine.
- Hyruan ONE is intended for single use only. No re-sterilization or reuse is allowed.
- The injection site must be sterilized either by alcohol or other disinfecting solution prior to administration.
- Used syringe, needle and unused materials all need to be discarded after administration.
- In case Hyruan ONE is administered into both sides of knee, a separate product should be applied for each administration.

3) Precautions in handling
- Hyruan ONE should be kept away from children.
- Hyruan ONE should be kept in original packaging; storing Hyruan ONE in a different packaging can cause misuse of product or decline the product quality.

Incompatibilities

Incompatibilities of Hyruan ONE with other drug substances have not been established.

Use in specific populations

1) Pregnancy
Safety and efficacy of Hyruan ONE in pregnant women have not been established so that Hyruan ONE should be cautiously administered to pregnant women or woman having possibility to be pregnant only when the benefits of treatments outweigh danger.

2) Nursing mothers
Safety and efficacy of Hyruan ONE in nursing mother have not been established, thus Hyruan ONE should be cautiously administered to nursing mother only when the benefits of treatments outweigh danger.

3) Pediatrics
The pediatric Safety and efficacy of Hyruan ONE have not been established thus Hyruan ONE should be administered to children with caution when administered unavoidably.

4) Geriatrics
Since physiological function of geriatrics has a declining tendency, administration should be made carefully. Difference in the incidence of reaction rate after administration of Hyruan ONE between geriatrics and non-geriatric group was not observed in the clinical trial.

Storage condition

Store at 1~30℃ free from light, in a hermetic container.

How supplied

3.0mL/syringe × 1syringe

Shelf life

24 months

※Date of Issue : February 11, 2015

Symbols on packaging

	Do not resterilize	1℃ 30℃	Temperature limitation
	Do not re-use		Keep away from sunlight
	Consult instructions for use	STERILE	Sterilized stream or dry heat
	Do not use if package is damaged		Keep away from rain
	Caution		Date of manufacture
	Manufacturer		Use-by date
LOT	Batch code		

LG Life Sciences
129, Seokam-ro, Iksan-si,
Jeollabuk-do, Korea